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Introduction
Although monoclonal antibodies have demonstrated remarkable efficacy as cancer therapeutics (1), only 
a limited number of  extracellular oncotargets have been explored to date, primarily because only extra-
cellular antigens have been regarded as accessible to antibody therapy. As a consequence, intracellular 
antigens, which have been considered “undruggable” antibody targets, have been traditionally inhibited 
with small molecules, despite the poorer target selectivity and, consequently, off-target side effects and 
clinical failures associated with this method (2, 3).
To address this gap, in 2008, we proposed an unconventional approach by selecting oncotargets from 
the large pool of  unexplored, previously deemed “undruggable,” intracellular oncoproteins for antibody 
therapy (4). We demonstrated that specific antibody-antigen recognition was essential and sufficient for 
efficient suppression of  tumors expressing the intracellular oncotargets in vivo. Subsequently, we followed 
up on these findings with a proof-of-concept study validating the feasibility and efficacy of  this concept by 
targeting additional endogenous and exogenous intracellular “tumor-specific antigens” with antibody ther-
apy and vaccination in wild-type C57BL/6 and transgenic spontaneous breast tumor MMTV-PyMT mice 
Novel, tumor-specific drugs are urgently needed for a breakthrough in cancer therapy. Herein, 
we generated a first-in-class humanized antibody (PRL3-zumab) against PRL-3, an intracellular 
tumor-associated phosphatase upregulated in multiple human cancers, for unconventional 
cancer immunotherapies. We focused on gastric cancer (GC), wherein elevated PRL-3 mRNA 
levels significantly correlated with shortened overall survival of GC patients. PRL-3 protein was 
overexpressed in 85% of fresh-frozen clinical gastric tumor samples examined but not in patient-
matched normal gastric tissues. Using human GC cell lines, we demonstrated that PRL3-zumab 
specifically blocked PRL-3+, but not PRL-3–, orthotopic gastric tumors. In this setting, PRL3-zumab 
had better therapeutic efficacy as a monotherapy, rather than simultaneous combination with 
5-fluorouracil or 5-fluorouracil alone. PRL3-zumab could also prevent PRL-3+ tumor recurrence. 
Mechanistically, we found that intracellular PRL-3 antigens could be externalized to become 
“extracellular oncotargets” that serve as bait for PRL3-zumab binding to potentially bridge and 
recruit immunocytes into tumor microenvironments for killing effects on cancer cells. In summary, 
our results document a comprehensive cancer therapeutic approach to specific antibody-targeted 
therapy against the PRL-3 oncotarget as a case study for developing antibodies against other 
intracellular targets in drug discovery.
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(5). Since then, three possible mechanisms for the antitumor activity of  such intracellular tumor antigen–
specific antibodies have been proposed, including antibody penetration into cells, antibody binding to exter-
nalized antigen, and/or antibody recognition of  MHC-bound antigen-derived peptides (6, 7). Collectively, 
this cancer immunotherapy approach demonstrates that intracellular oncoantigens are indeed tractable to 
antibody therapy in vivo, creating potentially new growth avenues for the future of  antibody-based cancer 
therapy (1, 8).
The most promising intracellular oncotarget from our early studies was phosphatase of  regenerating 
liver 3 (PRL-3, also known as PTP4A3), a member of  the PRL family of  dual-specificity protein tyrosine 
phosphatases that we identified in 1998 (9). PRL-3 is localized to the cytoplasmic face of  the plasma mem-
brane and endosomes via its prenylated C-termini (10). In 2001, Vogelstein and colleagues first charac-
terized PRL-3 as a metastasis-associated phosphatase, with specific upregulation in metastatic colorectal 
cancer samples but not primary cancers and normal colorectal epithelia (11). Elevated PRL-3 expression 
was also independently identified as the most significant predictor of  metastatic recurrence in uveal mela-
noma patients (12). Mounting evidence suggests that PRL-3 promotes multiple stages of  malignant trans-
formation (13) via activation of  PI3K/Akt, ERK, and SRC oncogenic pathways through downregulation 
of  PTEN (14) and/or activation of  upstream receptor tyrosine kinases (15–17). To date, elevated PRL-3 
mRNA expression levels have clinically been shown to correlate with higher metastatic potential and poor 
prognosis of  multiple cancer types (18).
Gastric cancer (GC) ranks as the third leading cause of  cancer mortality worldwide, with more than 
700,000 GC-related deaths annually (19), largely due to delayed detection and the asymptomatic nature 
of  the disease in its early stages, coupled to the high rate of  recurrence after treatment (20). PRL-3 
was first linked with GC progression in 2004 when it was found that higher PRL-3 levels correlated 
with increased GC invasiveness and metastasis (21). Since then, PRL-3 has been reported to be over-
expressed in up to 70% of  primary gastric carcinomas, with higher PRL-3 expression correlating with 
shorter postoperative survival at all tumor stages in GC patients (22, 23), underlining the particularly 
valuable prognostic potential of  PRL-3 in this morbid disease. Radical surgery is the first line treatment 
for GC, with adjuvant chemotherapy often given before and/or after resection (24, 25). However, overall 
survival with chemotherapy remains poor and is accompanied with undesirable side effects due to non-
specific targeting of  other actively dividing, noncancerous cells (20). To this end, targeted therapy using 
tumor-specific biological agents, particularly antibodies, has emerged as the frontier of  anticancer drug 
development due to their selective inhibition of  specific molecules involved in the growth and survival of  
cancer cells, while leaving normal cells unharmed. In GC, for example, the HER2/neu receptor antag-
onist trastuzumab (Herceptin) has been approved to target the 13%–20% of  GCs expressing cell surface 
HER2/neu receptors, particularly metastatic gastric or gastroesophageal junction adenocarcinoma (26, 
27). However, despite moderate responses, patients often develop resistance to trastuzumab (28), hinder-
ing its efficacy. Hence, better tumor-specific molecular targets and/or alternative therapeutic strategies 
for GC are desperately needed.
In this study, we explored the potential value of  PRL-3 as a tumor-specific oncotarget in gastric clinical 
samples as well as its suitability for antibody therapy to suppress PRL-3+ gastric tumor growth. Following 
the success of  murine and, more recently, chimeric (29) anti–PRL-3 antibodies in blocking PRL-3–express-
ing tumors, we herein advance this concept in four key aspects: (a) the use of  PRL-3–humanized antibodies 
(PRL3-zumab), instead of  mouse or chimeric antibodies to target PRL-3+ tumors; (b) the establishment of  
more clinically relevant orthotopic gastric tumor models, instead of  experimental mouse tail vein metas-
tasis models; (c) the characterization of  PRL3-zumab’s superior efficacy as a monotherapy, rather than 
simultaneous combination therapy with 5-fluorouracil (5-FU); and (d) the demonstration of  the profound 
value of  PRL3-zumab in preventing cancer recurrence after surgical removal of  PRL-3+ tumors.
Results
PRL-3 is an oncotarget specifically enriched in tumors but not in normal tissues. A pertinent challenge in the 
development of  anticancer-targeted therapy is the identification of  tumor-enriched antigens that are pref-
erentially expressed in tumors but not in normal tissues, so as to avoid undesirable off-target effects. We 
first screened murine normal tissues by Western blotting for endogenous PRL-3 expression. In our full, 
uncropped blots, PRL-3 monoclonal antibody detects only a single approximately 20-kDa endogenous 
protein — corresponding to PRL-3’s predicted molecular weight — showing that anti–PRL-3 antibody did 
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not cross-react with other molecules (Figure 1A). Although PRL-3 was weakly detected in normal colon 
and small intestine (Figure 1A, lanes 2 and 3), it was undetectable in 13 other major organs examined 
(Figure 1A, lanes 1 and 4–15), including normal breast and lung (Figure 1A, lanes 14 and 15). In contrast, 
PRL-3 was abundantly expressed in spontaneously developed breast and lung tumors (Figure 1A, lanes 
16 and 17) from MMTV-PyMT mice (30). In human tissues, PRL-3 was undetectable in most major nor-
mal organs examined by immunohistochemistry, with very weak expression detectable in normal colon 
and small intestine (Supplemental Figure 1A; supplemental material available online with this article; 
doi:10.1172/jci.insight.87607DS1), mirroring our observation in murine tissues (Figure 1A). Consistent 
with its tumor-specific upregulation, PRL-3 was undetectable in normal gastric tissue, yet highly expressed 
in adjacent gastric tumor sections from the same patient (Supplemental Figure 1B). It is worth noting that 
mice deficient for PRL-3 appear grossly normal (31), suggestive of  the dispensability of  PRL-3 function in 
normal tissues. Taken together with our results here, the high expression of  PRL-3 in tumor, but not nor-
mal, tissues, coupled with the high frequency of  PRL-3 overexpression observed in multiple cancers (32), 
establishes PRL-3 as an ideal tumor-enriched oncotarget.
PRL-3 oncoprotein is overexpressed in 85% of  gastric tumors examined. Over the past decade, a number of  
studies have demonstrated elevated PRL-3 expression as a negative prognostic factor for GC (21, 33, 34). We 
further validated the clinical significance of  PRL-3 overexpression in GC by two independent approaches. 
First, we analyzed the clinical characteristics of  patients with upregulated PRL-3 mRNA levels in a cohort of  
185 GC patients (clinical characteristics given in Supplemental Table 1). In multivariate Cox analysis, high 
PRL-3 mRNA expression was significantly associated with higher tumor grades (Supplemental Table 2) and 
shorter overall survival (Kaplan-Meier survival analysis, P = 0.002; Figure 1B), consistent with indepen-
dent observations in other GC cohorts (21, 33, 34). Second, we examined the levels of  PRL-3 protein using 
matched, fresh-frozen biopsy gastric tissue sample pairs (tumor-adjacent normal samples) from 20 random-
ly selected GC patients. Western blots clearly showed endogenous PRL-3 overexpressed in 17 of  20 (85%) 
gastric tumors (Figure 1C). In contrast, PRL-3 was not detected in any matched normal gastric samples 
Figure 1. PRL-3 is an oncotarget highly expressed in tumor tissues. (A) Western blots of PRL-3 in various normal tissues of FVB/wild-type mice (lanes 
1–15) and spontaneous breast and metastatic lung tumors from FVB/MMTV-PyMT mice (lanes 16 and 17). HSP60, loading control. (B) Kaplan-Meier 
survival analysis of PRL-3 mRNA expression in the Singapore (SGSet1) gastric cancer (GC) patient cohort. n = 183; P = 0.002, log-rank test. (C) Full Western 
blot analysis of PRL-3 in 20 pairs of human primary gastric tumors (T) versus patient-matched normal stomach tissues (n) from 20 random GC patients. 
GAPDH, loading control; Mr, relative molecular mass (kDa).
Downloaded from http://insight.jci.org on June 19, 2016.   http://dx.doi.org/10.1172/jci.insight.87607
4insight.jci.org   doi:10.1172/jci.insight.87607
R E S E A R C H  A R T I C L E
(Figure 1C), validating the tumor-specific 
expression of  PRL-3. Notably, PRL-3 pro-
tein appeared as a broad band between 20 
and 25 kDa in these full blots, suggestive of  
extensive potential posttranslational modi-
fications of  PRL-3 — such as its previously 
reported acetylation and/or phosphoryla-
tion (35, 36) — in human tumor samples. 
Taken together, the frequent overexpression 
of  PRL-3 in clinical GC samples, coupled 
with the correlation of  elevated PRL-3 
expression with disease severity, reaffirms 
PRL-3 as an excellent candidate for target-
ed GC therapy.
Generation of  a PRL-3–targeting human-
ized antibody, PRL3-zumab. We previously 
demonstrated the high efficacy of  murine 
and chimeric anti–PRL-3 monoclonal antibodies against metastatic tumors expressing intracellular PRL-3 
in both nude and wild-type C57BL/6 mice (5, 29). In these studies, mice receiving PRL-3 monoclonal 
antibodies gained weight continuously and displayed normal activities, suggesting minimal off-target side 
effects. To translate these early findings towards clinical application in humans, we engineered a human-
ized monoclonal anti–PRL-3 antibody, hereafter called “PRL3-zumab,” based on these scaffolds. Like its 
predecessors, PRL3-zumab specifically recognizes both mouse and human PRL-3 isoforms equally well 
and does not cross-react with the homologous PRL-1 or PRL-2 proteins by Western blotting, ELISA, or 
immunofluorescence analysis (Supplemental Figure 2, A–D). Subsequently, we used PRL3-zumab for all 
further experiments described in this report.
PRL3-zumab specifically inhibits PRL-3+ but not PRL-3– orthotopic gastric tumors. Human cancer cells grow-
ing in their natural (orthotopic) locations in mouse tumor models replicate human disease with high fidel-
ity. More importantly, tumor responses to therapy have been shown to vary dramatically depending on 
whether cancer cells are implanted in a subcutaneous versus an orthotopic location (37), highlighting the 
requirement of  choosing the right model for assaying therapeutic efficacies of  antitumor agents. To estab-
lish a relevant preclinical orthotopic murine model to examine the efficacy of  PRL3-zumab against gastric 
tumors, we first screened a panel of  22 human GC cell lines for PRL-3 protein expression status and sub-
sequently tested their tumorigenic capacity within the subserosa layer of  stomachs in mice. PRL-3 protein 
was detected in 13 of  22 (59%) of  human GC cell lines analyzed (Figure 2A). However, only a subset 
Figure 2. PRL3-zumab specifically blocks PRL-
3+ (but not PRL-3–) orthotopic gastric tumors. 
(A) Western blot for endogenous PRL-3 in 22 
human gastric cancer (GC) cell lines. Tum-
origenic PRL-3+ or PRL-3– cell lines selected for 
subsequent animal models are indicated with a 
red asterisk. Mr, relative molecular mass (kDa). 
(B) Outline of the experimental orthotopic GC 
model in BALB/c nude mice. (C) PRL3-zumab 
inhibits PRL-3+ SNU-484 orthotopic gastric 
tumor growth. Top panels: mouse appearance 
at the end of the experiment (day 28). Arrows 
indicate abdominal distention in untreated 
mice. Bottom panels: excised stomachs with 
tumor areas framed in black lines. Scale bar: 
10 mm. (D) Mean gastric tumor volumes in 
untreated and treated groups at day 28. n = 8 
per group; P = 0.01, t test; data represent mean 
± SEM. (E) Kaplan-Meier survival analysis of 
untreated (red lines) and treated (black lines) 
groups of mice. n = 4 per group; P = 0.006, 
log-rank test.
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of  these GC cell lines grew well in culture and robustly formed orthotopic tumors within a reasonable 
timeframe (<3 months). Based on these criteria, three PRL-3+ cell lines (SNU-484, NUGC-4, and IM-95) 
and one PRL-3– cell line (MKN45) were selected for developing orthotopic GC models to assess the ther-
apeutic efficacy of  PRL3-zumab. Cells were inoculated into the subserosa layer of  the stomach, and mice 
were subsequently administered with placebo (untreated) as control or PRL3-zumab (treated) following the 
protocol outlined in Figure 2B. At the end of  the experiment, stomachs were harvested and analyzed for 
gastric tumor burden.
We first studied the effect of  PRL3-zumab treatment on the orthotopic gastric tumors formed by the 
PRL-3+ SNU-484 GC cell line, which served as an ideal cell line for this study due to its high expression 
of  PRL-3 protein (Figure 2A, lane 1), rapid growth in cultures, and reproducible orthotopic gastric tumor 
formation within 3 to 4 weeks. Over the course of  the experiment (Figure 2B), untreated mice developed 
pronounced abdominal distention, whereas treated mice maintained a grossly normal appearance (Figure 
2C, top). Upon dissection, orthotopic tumor formation was visibly reduced in the treated group compared 
with the untreated group (Figure 2C, bottom). Measurement of  tumor volume revealed a significant 20-fold 
reduction of  tumor burden in the treated group versus untreated group (Figure 2D, 0.23 ± 0.25 cm3 vs. 4.08 
± 1.52 cm3; P = 0.01). This phenomenon was unrelated to nonspecific effects of  humanized IgG in mice, 
as administration of  human IgG isotype control antibodies did not result in reduced tumor burden (Sup-
plemental Figure 3). Furthermore, despite stopping treatment after 10 doses (5 weeks), treated mice had a 
significantly longer overall survival compared with untreated mice, with a median survival time of  7 weeks 
versus 4.5 weeks, respectively (Figure 2E; Kaplan-Meier survival analysis, P = 0.006). These results suggest-
ed that mice carrying PRL-3+ SNU-484 gastric tumors responded effectively to PRL3-zumab therapy. To 
Figure 3. PRL3-zumab has therapeutic effects when negative tumors forced PRL-3 overexpression. (A) PRL3-zumab could not block PRL-3– MKN45 
orthotopic gastric tumor growth. Top panels: mouse appearance at the end of the experiment (day 56). Bottom panels: excised stomachs with tumor areas 
framed in black lines. Scale bar: 10 mm. (B) Mean gastric tumor volumes from A at day 56. n = 8 per group; P = 0.45, t test; data represent mean ± SEM. (C) 
Kaplan-Meier survival analysis of untreated (red lines) and treated (black lines) groups of mice. n = 4 per group; P = 0.3, log-rank test. (D) Western blot for 
overexpressed EGFP-PRL-3 in MKN45-PRL-3 cells. GAPDH, loading control; Mr, relative molecular mass (kDa). (E) Immunofluorescence of the MKN45 cell 
pool stably overexpressing GFP-PRL-3 (MNK45-PRL-3). Scale bar: 20 μm. (F) PRL3-zumab effectively blocks MKN45-PRL-3 orthotopic gastric tumor growth. 
Top panels: mouse appearance at the end of the experiment (day 28). Bottom panels: excised stomachs with tumor areas framed in black lines. Scale bar: 10 
mm. (G) Mean gastric tumor volumes from F at day 28. n = 4 (untreated group) or 5 (treated group); P = 0.00002, t test; data represent mean ± SEM.
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validate this finding, orthotopic GC murine models were generated using two additional PRL-3+ human 
GC cell lines, IM-95 and NUGC-4 (Figure 2A, lanes 2 and 22, respectively). Similar to SNU-484 ortho-
tropic tumors, PRL3-zumab treatment resulted in significantly reduced volumes of  both PRL-3+ IM-95 
(Supplemental Figure 4A; P = 0.008) and PRL-3+ NUGC-4 (Supplemental Figure 4B; P = 0.03) tumors.
In contrast, gastric tumors formed by the PRL-3– MKN45 GC cell line (Figure 2A, lane 4) showed no 
response to PRL3-zumab treatment, with pronounced abdominal distention (Figure 3A, top) and orthot-
opic tumor formation (Figure 3A, bottom). No difference in mean orthotopic tumor volume was found 
between treated (0.26 ± 0.22 cm3) and untreated (0.19 ± 0.13 cm3) groups (Figure 3B; P = 0.45). Likewise, 
there was no significant difference in overall survival between the two groups, with median survival at 9.25 
weeks in the untreated group versus 10 weeks in treated group (Figure 3C; Kaplan-Meier survival analysis, 
P = 0.3), suggesting that MKN45 tumors lacking PRL-3 oncotarget did not respond to PRL3-zumab treat-
ment. To address the possibility that MKN45 cells might be generally resistant to anticancer therapy, we 
overexpressed EGFP-tagged PRL-3 in MKN45 cells (MKN45-PRL-3; Figure 3, D and E) and attempted 
treatment with PRL3-zumab again. In line with PRL-3’s pro-oncogenic functions in GC cells, MKN45-
PRL-3 cells formed aggressive orthotopic tumors in untreated mice (Figure 3F, left) in a shorter time 
frame than MKN45 cells. Importantly, these pathological phenotypes could be strongly suppressed upon 
PRL3-zumab treatment (Figure 3F, right). Measurement of  tumor volume revealed a significant 10-fold 
reduction of  tumor burden in the treated group versus the untreated group (Figure 3G, 0.04 ± 0.03 cm3 vs. 
0.39 ± 0.06 cm3; P = 0.0002). This is in stark comparison with PRL-3– MKN45 parental cells (Figure 3, 
A–C), suggesting that while forced PRL-3 expression promoted more aggressive GC tumor growth in vivo, 
it concurrently endowed responsiveness to PRL3-zumab treatment. Collectively, the results of  PRL3-zum-
ab treatment of  orthotopic tumors derived from these 5 cell lines (summarized in Table 1) cement a fun-
damental principle underlying PRL-3 antibody therapy (5) — only PRL-3–expressing tumors respond to 
PRL3-zumab therapy, while tumors lacking PRL-3 expression do not.
PRL3-zumab is more effective as a monotherapy than when coadministered with 5-FU or 5-FU alone. 5-FU is 
a chemotherapeutic drug used as first-line treatment of  GC (20). To study whether PRL3-zumab may 
synergize with 5-FU in inhibiting orthotopic tumor growth, we tested 4 treatment protocols: placebo as 
untreated control (group 1), PRL3-zumab monotherapy (group 2), PRL3-zumab and 5-FU combination 
therapy (group 3), or 5-FU monotherapy (group 4). Dependent on the treatment protocol, biweekly doses of  
PRL3-zumab (100 μg/dose) or 5-FU (30 mg/kg/dose) were administered individually or in combination i.v. 
into groups of  nude mice carrying orthotopic PRL-3+ SNU-484 gastric tumors. PRL3-zumab monotherapy 
(group 2) showed the highest therapeutic efficacy, with the lowest mean tumor volume of  0.67 ± 0.59 cm3, 
followed by the PRL3-zumab and 5-FU combination treatment (group 3; 1.49 ± 0.27 cm3), 5-FU monother-
apy (group 4; 1.76 ± 0.52 cm3), and, finally, the placebo control group (group 1; 3.98 ± 0.60 cm3; Figure 4A). 
One-way ANOVA revealed a statistically significant difference across all groups (F3,16 = 40.09, P < 0.001) as 
well as between groups (Supplemental Table 3). These results show that PRL3-zumab has more therapeutic 
efficacy when used without the chemotherapeutic drug, 5-FU.
The host immune system plays an important role in the efficacy of  PRL-3 antibody therapy (5). In light 
of  the known side effects of  5-FU treatment in causing a reduction in the numbers of  white blood cells (wbc) 
(38), we investigated whether the reduction in therapeutic efficacy observed might be due to this phenom-
enon. In whole-blood smears, we found a 5-fold reduction in peripheral wbc counts after 5-FU treatment 
Table 1. Summary of PRL3-zumab treatment outcomes in orthotopic models of 5 human GC cell lines
Mean tumor volume ± SEM (cm3)
Cell line PRL-3 status Untreated n Treated n P value
SNU-484 PRL-3+ 4.08 ± 0.54 8 0.23 ± 0.89 8 0.01
NUGC-4 PRL-3+ 0.30 ± 0.1 4 0.02 ± 0.01 4 0.03
IM-95 PRL-3+ 0.14 ± 0.03 6 0.01 ± 0.003 6 0.0008
MKN45 PRL-3– 0.19 ± 0.05 8 0.26 ± 0.08 8 0.45
MKN45-PRL-3 PRL-3+ 0.39 ± 0.03 4 0.07 ± 0.02 5 0.00002
Data are presented as mean ± SEM.
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(groups 3 and 4) compared with control (group 1) 
or PRL3-zumab monotherapy (group 2; Figure 
4B). Although 1-way ANOVA analysis revealed a 
statistically significant difference across all groups 
(F3,16 = 224.26, P < 0.001), no significant differ-
ence in wbc counts was found between control and 
PRL3-zumab monotherapy groups (Supplemental 
Table 4; P = 0.438), suggesting that wbc counts 
were unaffected by PRL3-zumab treatment. To val-
idate these results, we performed full blood counts 
at the end of  the experiment (day 28) to analyze the 
hematological effects of  the different treatment reg-
imens. Whereas mice receiving PRL3-zumab had a 
general hematological profile within the normal ref-
erence range for the BALB/c nude strain (39), those 
receiving 5-FU in combination with PRL3-zumab, 
or 5-FU alone, displayed pronounced leucopenia, 
with reduced neutrophil, lymphocyte, and mono-
cyte counts as well as marked reductions in rbc and 
platelets (Table 2). Along with this hematological 
defect, during the course of  the experiment, we 
also observed a reduction in overall animal activity 
in 5-FU–treated mice. Taken together, our results 
suggest that the reduction in immune function as 
a result of  5-FU treatment may account for the 
reduced efficacy of  PRL3-zumab when used in 
combination with 5-FU.
PRL3-zumab therapy suppresses recurrence of  post-
operative PRL-3+ tumors. Although surgery is the 
cornerstone in the treatment of  GC, nearly 80% of  
patients die within a short period of  time after sur-
gery, largely due to locoregional recurrence and/or, 
to a lower extent, distant metastasis (40). In light 
of  PRL3-zumab’s ability to suppress PRL-3+ GC 
growth in vivo, we investigated whether PRL3-zum-
ab also had efficacy as a postoperative adjuvant 
treatment to suppress tumor recurrence. Using 
PRL-3+ SNU-484 GC cells, we first established 
Figure 4. PRL3-zumab is more effective as a mono-
therapy rather than when coadministered with 
5-fluorouracil or 5-fluorouracil alone. Four treatment 
groups were used to treat PRL-3+ SNU-484 orthotopic 
tumors: placebo (group 1), PRL3-zumab monothera-
py (group 2), PRL3-zumab and 5-fluorouracil (5-FU) 
combination therapy (group 3), or 5-FU alone (group 4). 
(A) Excised stomachs from each group of mice at day 
28, with orthotopic tumor areas framed with black lines, 
and mean gastric tumor volumes in each group at day 
28. Scale bar: 10 mm. n = 5 per group; P < 0.001, 1-way 
ANOVA; data represent mean ± SEM. (B) Representa-
tive images of Giemsa-stained blood smears from each 
group before the start of therapy (day 0) and at the 
end of the experiment (day 28) and mean wbc count 
from blood smears from each mouse at day 28. wbc 
are stained blue. Scale bar: 40 μm. n = 5 per group; P < 
0.001, 1-way ANOVA; data represent mean ± SEM.
Table 2. Hematological profiles of mouse groups at the end of the various 








wbc count 3.48–14.03 × 109/l 4.83 1.10A 0.60A
Neutrophils 0.58–3.83 × 109/l 1.65 0.04A 0.03A
Lymphocytes 2.22–9.83 × 109/l 3.03 0.98A 0.54A
Monocytes 0.21–1.25 × 109/l 0.16 0.03A 0.03A
Eosinophils 0.01–0.49 × 109/l 0.00 0.02 0.00A
Basophils 0.00–0.18 × 109/l 0.01 0.04 0.01
RBC count 6.93–12.24 × 1012/l 6.97 5.07A 4.87A
Hemoglobin 12.6–20.5 g/dl 10.4A 7.4A 7.1A
MCV 50.7–64.5 fl 58.3 49.3A 47.7A
MCH 13.2–17.6 pg 15.0 14.7 14.7
MCHC 23.3–32.7 g/dl 26.0 29.3 21.7
Platelet 420–1,698 × 109/l 1,016 202A 198A
AOutliers from the normal reference range for BALB/c nude mice. Data are presented as 
mean values; n = 3 per group. 
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xenografts in both flanks of  nude mice over the 
course of  3 weeks (Figure 5A, top image). The 
resulting tumors were then completely removed 
via careful surgical resection (Figure 5A, mid-
dle image), and mice were injected biweekly, 
for 5 weeks, with either placebo (untreated) 
or PRL3-zumab (treated). Tumor recurrence, 
defined herein as regrowth of  tumors with diam-
eter greater than or equal to 0.5 cm at each resec-
tion site, was monitored for up to 10 weeks after 
resection. Whereas all untreated mice had recur-
rent tumors at resection sites, none were observed 
in treated mice over the 10-week study duration 
(Figure 5A, bottom image). Accordingly, treated 
mice had a significantly longer recurrence-free 
survival compared with untreated mice (Figure 
5B; Kaplan-Meier survival analysis, P < 0.001). 
Collectively, these results suggest that PRL3-zum-
ab has efficacy in suppressing postoperative local 
tumor recurrence.
PRL3-zumab suppresses growth and regional 
spread of  xenograft PRL-3+ tumors in a stomach colo-
nization model. Metastasis to the stomach is a rare 
condition (41–43), which is almost invariably 
associated with poor prognosis (44, 45). To indi-
rectly address whether PRL3-zumab could block stomach colonization by disseminated, non-GC cells, 
we developed a model using PRL-3+ HCT116-luc2 colorectal cancer cells (29) surgically implanted within 
the subserosa layer of  mouse stomachs. We chose HCT116-luc2 cells for this model because (a) colorectal 
cancer metastasis to stomach is clinically relevant (42, 43, 46), (b) HCT116-luc2 cells robustly and rapidly 
form tumors within the gastric niche, and (c) HCT116-luc2 cells constitutively express firefly luciferase, 
allowing noninvasive monitoring of  tumor growth using an In Vivo Imaging System (IVIS). In two biologi-
cal replicates, whereas PRL-3+ HCT116-luc2 colorectal cancer cells rapidly established large tumors within 
the abdominal region of  untreated mice, mice treated with PRL3-zumab had suppressed PRL-3+ tumor 
growth (Supplemental Figure 5A). Two-way ANOVA analysis of  the change in global tumor luminescence 
intensities over 3 weeks revealed a statistically significant difference between untreated and treated groups 
(Supplemental Figure 5B; F2,18 = 16.731, P < 0.001). Heavier HCT116-luc2 tumor burden was confirmed 
Figure 5. PRL3-zumab prevents PRL-3+ tumor recur-
rence and prolongs survival after tumor resection. 
(A) Xenograft tumors, formed by PRL-3+ SNU-484 cells 
injected s.c. and grown for 3 weeks on both flanks 
of nude mice, were surgically removed once they 
reached 0.5–1 cm in diameter. Mice were subsequently 
divided into placebo (untreated) or PRL3-zumab 
(treated) groups and treated biweekly for a maximum 
of 5 weeks (10 doses). Treatment was subsequently 
stopped and tumor regrowth was monitored for 
another 5 weeks. Top image: tumor-bearing mouse 
appearance at the end of 3 weeks. Middle image: 
mouse appearance after surgical resection of tumors, 
with dissected tumors shown. Bottom image: mouse 
appearance at the end of the experiment, with 
dissected tumors recurring at resection sites shown. 
Scale bar: 10 mm. (B) Kaplan-Meier recurrence-free 
survival analysis of untreated (red lines; n = 10) and 
treated (black lines; n = 8) groups of mice. P < 0.001, 
log-rank test.
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in stomachs of  untreated mice compared with treated mice (Supplemental Figure 5C), with significantly 
smaller gastric tumors in the latter (Supplemental Figure 5D; P < 0.001). Furthermore, the extensive meta-
static tumors attached to abdominal walls seen in untreated mice were also significantly reduced in treated 
mice (Supplemental Figure 5, E and F; P = 0.0003). These results demonstrate that PRL3-zumab can also 
reduce growth and regional spreading of  secondary tumors in and around the gastric niche.
Possible mechanism of  action for PRL3-zumab suppression of  PRL-3+ tumors. Studies on autoimmune pathol-
ogies have shown that autoantibodies can bind specific intracellular antigens and accumulate within the 
cytoplasm and nuclear compartments of  antigen-expressing cells (47). Likewise, we have observed that anti–
PRL-3 antibodies can be internalized by PRL-3+ tumor cells in vitro (4). However, the mode of  antibody 
uptake remains poorly defined. Here, we uncover two findings by which intracellular PRL-3 antigens might 
engage antibodies for specific binding and tumor suppression. (a) Intracellular PRL-3 oncoprotein can be 
secreted out. In tumor cells, several classically “intracellular” proteins have been reported to be externalized 
via secretion and/or cell surface relocalization, thereby making them accessible to therapeutic intervention 
using antibodies (48, 49). We investigated whether PRL-3 might likewise be externalized as a target antigen 
for PRL3-zumab binding by comparing PRL-3 intracellular and extracellular PRL-3 expression in three 
PRL-3+ cell lines, SNU-484, NUGC-4, and IM-95, and one PRL-3– cell line, MKN45. PRL-3 expression 
was compared with the nonsecreted, ER-anchored protein, calnexin, as a control. PRL-3 protein was detect-
ed both in intracellular protein fractions (cell lysates) of  PRL-3+ GC cells (Figure 6A, lanes 1–3) as well 
as in extracellular protein pools (concentrated conditioned media) of  PRL-3+ GC cells (Figure 6A, lanes 
5–7) but not PRL-3– GC cell lines (Figure 6A, lanes 4 and 8). In contrast, calnexin was exclusively present 
in intracellular pools of  both PRL-3+ and PRL-3– GC cells (Figure 6A, lanes 1–4) but not in extracellular 
pools (Figure 6A, lanes 5–8). This observation ruled out nonspecific contamination by dead cells or cellu-
lar debris and characterizes PRL-3 as a novel secreted protein. (b) Externalized PRL-3 may serve as bait 
for PRL3-zumab binding. We next investigated the tumor sections from treated orthotopic GC mice and 
analyzed the distribution of  PRL3-zumab within the tumor niche. As a control, no signals were seen in 
untreated mice (Figure 6B, leftmost panels). Following treatment, PRL3-zumab was enriched within PRL-3+ 
SNU-484 tumor microenvironments, regardless of  5-FU coadministration (Figure 6B). In contrast, no 
enrichment was observed in PRL-3– MKN45 tumor microenvironments (Figure 6B). These results indicated 
a specific accumulation of  PRL3-zumab in the microenvironment of  PRL-3+ tumors but not PRL-3– tumors.
Figure 6. PRL-3 oncoprotein may be secreted out of cancer cells and act as bait for PRL3-zumab. (A) Analysis of PRL-3 protein expression in intracellular 
protein pools (cell lysate) and extracellular protein pools (concentrated conditioned media) after culturing gastric cancer (GC) cells in serum-free media for 
48 hours. For extracellular protein analysis, conditioned media (50 ml) from 5 dishes of GC cells were first cleared of dead cells and cellular debris, followed 
by centrifugal concentration (final volume ~0.2 ml). Mr, relative molecular mass (kDa). (B) Orthotopic SNU-484 and MKN45 tumor tissue cryosections from 
mice subject to various treatments were analyzed by immunohistochemistry for PRL3-zumab using anti-human IgG antibodies. Scale bar: 20 μm.
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Discussion
This study characterizes PRL-3 as a tumor-specific oncotarget, establishes orthotopic gastric models for 
proof-of-concept preclinical studies, and establishes PRL3-zumab as a clinically translatable drug candidate 
against PRL-3+ tumors. We demonstrated the marked therapeutic efficacy of  PRL3-zumab directed against 
intracellular PRL-3–expressing primary gastric tumors and secondary colorectal tumors within the stom-
ach niche as well as its value as an adjuvant in postoperative therapy to prevent tumor recurrence. Concep-
tually, this study further demonstrates the previously unrecognized potential of  tumor-specific intracellular 
oncoproteins as viable molecular targets for specific antibody cancer therapy.
To create a clinically relevant orthotopic GC model using human GC cell lines, we employed immu-
nodeficient nude mice instead of  severely immunocompromised mice strains, such as NOD/SCID, BAL-
B/c-RAG2null, or their derivatives (50). These latter strains have little or no endogenous immune system 
intact, creating a gap in translating research findings to immunocompetent human patients. The use of  
a more clinically relevant mouse model also overcomes the limitations of  in vitro drug screening in cell 
culture systems, which are unable to recapitulate the complex interactions within the body and are poorly 
predictive of  in vivo toxicity (51). Our finding of  secreted PRL-3 oncoprotein sheds light onto the recog-
nition mechanism for antibody binding and targeting to PRL-3+ tumors. The specific externalization of  
classically “intracellular” proteins in cancer cells and their viability as therapeutic antibody targets have been 
well studied (48, 49, 52). Indeed, marked amounts of  intracellular material have long been reported to be 
spontaneously released from malignant cells into tumor microenvironments and extracellular fluids (53, 54). 
It is reasonable to anticipate that in vivo greater secretion of  intracellular oncoproteins occurs due to tumor 
tissues consistently being under immune surveillance and attack, thereby establishing an inflammatory state 
that results in apoptosis and/or necrosis of  tumor cells (55) and further nonspecific leakage of  intracellular 
content. Recognition of  antibodies by immune effector cells occurs via immunoglobulin receptors (FcRs), 
which bind the Fc portion of  antibodies, resulting in recruitment and activation of  effector cells (56), such as 
B and NK cells, two FcR-bearing immune cell types suggested to be involved in intracellular antibody thera-
py (7). Under such conditions, externalized “intracellular” tumor antigens could be recognized by antibodies 
in vivo to (a) induce antibody-dependent cellular cytotoxicity by recruitment of  NK cells, (b) form immune 
complexes (for secreted antigens) that can then be processed by regional dendritic cells for presentation 
and activation of  NK cells, or (c) target cells for antibody-dependent cellular phagocytosis by macrophages, 
which has lately been characterized as a major mechanism of  action behind many antibodies approved to 
treat cancer (57). Supporting this hypothesis, anti–PRL-3 antibodies have been shown to lack anticancer 
efficacy in immunocompromised SCID mice (5), or when directly added to PRL-3+ cancer cells in vitro (29), 
indicating the importance of  the interaction of  the therapeutic agent with immune effectors for successful 
treatment. Interestingly, PRL-3 was recently shown to promote secretion of  ULBP2, an NKG2D ligand, 
resulting in reduced tumor recognition and cytolysis by NK cells (58). Nonetheless, the effective tumor 
suppression seen in PRL3-zumab–treated mice suggests that PRL3-zumab allows the host to overcome this 
immune evasion mechanism, resulting in more efficient targeting of  PRL-3+ tumors.
In our study, PRL-3 oncoprotein was overexpressed in greater than 80% of the GC samples examined. With 
such a high PRL-3 tumor positivity, the development of PRL3-zumab–targeted therapy against tumor-specific 
PRL-3 is an exciting step towards personalized medicine. By maximizing therapeutic benefits and minimizing 
off-target side effects — PRL-3 is not expressed at detectable levels in most normal adult tissues — PRL3-zum-
ab justifies clinical validation and development as a precision anticancer drug. Although our results here focus 
on GC, PRL-3 has also been extensively linked to multiple cancer types of tumor metastasis and poor prog-
nosis, with higher PRL-3 expression associated with shorter overall survival (18). Based on the principle that 
PRL3-zumab exerts its effects only upon recognizing PRL-3 antigen, it is envisaged to have efficacy in targeting 
most, if  not all, PRL-3+ cancers, opening a new therapeutic avenue in general cancer therapy.
In summary, our findings here and elsewhere (4, 5, 29) challenge the dogma that intracellular oncoan-
tigens are inaccessible to therapeutic antibodies for anticancer effects. We suggest that other intracellular 
tumor-specific antigens could likewise have tremendous potential for targeted immunotherapy (6), prompt-
ing their reevaluation as tractable molecular targets in future clinical trials.
Methods
Preparation of  tissue and cell lysates. Multiple normal mouse organs were harvested from FVB/wild-type 
mice, whereas breast and metastatic lung tumors were dissected from the isogenic FVB/MMTV-PyMT 
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mice strain — a well-established spontaneous model of  metastatic breast cancer driven by transgenic over-
expression of  mammary-specific polyoma virus middle T oncogene (30) — obtained from the Biological 
Resource Centre (A*STAR). For tissues, excised samples (5 mm3) were suspended in RIPA lysis buffer (Sig-
ma-Aldrich) containing a protease-phosphatase inhibitor cocktail (Pierce) and disrupted completely with a 
tissue homogenizer (Polytron). Lysates were clarified by centrifugation at 13,000 g for 40 minutes at 4°C. 
For cell lines, 5 × 106 cells were lysed in RIPA lysis buffer containing a protease-phosphatase inhibitor and 
clarified as described above. Protein concentrations were estimated using a bicinchoninic assay kit (Pierce). 
After addition of  2× Laemmli buffer, samples were boiled and used immediately for Western blotting or 
stored at –20°C until use.
Western blotting. Tissue lysates (40 μg) or cell lysates (200 μg) were resolved in 12% SDS-polyacrylamide 
gels and transferred to nitrocellulose membranes before blocking and probing with the indicated primary 
antibodies at a 1:1,000 dilution overnight at 4°C. After thorough washing with TBS-T buffer (20 mM Tris 
pH 7.6, 140 mM NaCl, 0.2% Tween-20), the membrane was incubated with the respective HRP-conjugated 
secondary antibodies at a 1:5,000 dilution for 1 hour, washed with TBS-T buffer, and visualized using a 
chemiluminescent substrate (Pierce). Band intensities were calculated using ImageJ software (NIH).
Cell culture. The 22 human GC cell lines studied were obtained from the following sources: MKN7, 
MKN74, NUGC-3, and OCUM-1 (Health Science Research Resources Bank); YCC-1, YCC-3, YCC-7, and 
YCC-17 cells (Yonsei Cancer Centre); AGS, CRL-5822, KATO-III, SNU-1, and SNU-5 (ATCC); HGC27, 
NUGC-4, and OE19 (Sigma-Aldrich); MKN28 and MKN45 (RIKEN BioResource Center); IM-95 and 
SCH (Japanese Collection of  Research Bioresources Cell Bank); and SNU-484 and SNU-719 (Korean Cell 
Line Bank). CHO cells were purchased from ATCC. The generation of  CHO cells stably expressing GFP-
tagged PRL-1, PRL-2, or PRL-3 fusion proteins has been previously described (4). CHO and MKN45 cells 
stably expressing GFP-tagged isoforms of  human PRL-1, PRL-2, or PRL-3 were similarly established by 
transfection with plasmids generated by subcloning the respective human ORFs from previously generated 
pGEX-KG-PRL-1, pGEX-KG-PRL-2, or pGEX-KG-PRL-3 vectors (59) into pEGFP-C1 vectors (Clon-
tech), followed by selection in 1 mg/ml G418 (Sigma-Aldrich) for 2 weeks. Luciferase-expressing HCT116-
luc2 human adenocarcinoma cells (Caliper Life Sciences) were established by stably transducing lentivirus 
containing the luciferase 2 gene under the control of  human ubiquitin C promotor (pGL4 luc2) into paren-
tal HCT116 cells (ATCC). Cell lines were cultured in RMPI-1640 medium (Gibco) supplemented with 
10% heat-inactivated fetal bovine serum (Hyclone) and 1% penicillin-streptomycin (Life Technologies) and 
maintained in a 37°C incubator supplemented with 5% CO2.
Generation of  PRL3-zumab. The PRL3-zumab construct was engineered from the original framework 
of  the previously characterized murine anti–PRL-3 antibody clone 318 (59) independently by two CROs 
using a proprietary modification of  the method described by Queen et al. (60). Briefly, the complemen-
tarity determining regions (CDR) of  the heavy (IgG1) and light (κ) chains of  the mouse antibody were 
grafted onto “acceptor” human sequence frameworks, where the framework is defined as the segment of  
the variable regions excluding the CDRs. The choice of  human acceptor frameworks was made by align-
ing the mouse framework sequences against a database of  human framework sequences to find the closest 
human homolog for each chain (typically 65%–70% sequence identity). In addition to grafting the CDRs 
from the mouse sequence, about 3 amino acid positions from the mouse sequence (in addition to the 
CDRs) were also grafted into the human acceptor sequence. This preserved the original murine anti–PRL-
3 antibody’s CDR, which specifically recognizes an epitope within a C-terminal region conserved between 
both mouse and human PRL-3, but not PRL-1 or PRL-2. PRL3-zumab was subsequently purified from 
the culture media of  stably transfected CHO master cell lines. Binding affinity analysis, conducted by 
Sapidyne Instruments using a kinetic exclusion assay (61), characterized purified PRL3-zumab to have a 
KD of  6.29 pM to purified human PRL-3, with an on rate (Kon) and off  rate (Koff) of  approximately 1 × 10
7 
M–1s–1 and 7 × 10–5 s–1, respectively.
Analysis of  PRL-3 mRNA expression. We analyzed the publically available GC microarray data set 
(GSE15459) from the Gene Expression Omnibus database, consisting of  200 primary GC specimens pro-
filed on Affymetrix Human Genome U133 Plus 2.0 Genechip arrays. Data preprocessing was carried out 
using the “affyPLM” R package (v2.15). Outliers were excluded, giving a total of  185 tumor samples avail-
able for downstream analyses (SGset1; patient characteristics are provided in Supplemental Table 1). Sur-
vival analyses, with overall survival as the outcome metric, were performed to compare tumors (n = 183; 
2 samples missing survival data), with “low,” “medium,” and “high” expression of  the respective genes, 
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i.e., “low” and “high” expression groups correspond to samples with lower than the 33.3 percentile expres-
sion levels and greater than the 66.7 percentile expression levels, respectively, while the middle percentile 
was classified as “medium.”
Preparation of  recombinant GST-tagged proteins. The preparation of  recombinant GST-PRL-1, GST-
PRL-2, and GST-PRL-3 fusion proteins has been described previously (59).
ELISA. ELISA was performed as described previously (59). Briefly, 96-well plates coated overnight 
with GST-PRL-1 (20 ng), GST-PRL-2 (20 ng), or GST-PRL-3 (1 ng) were blocked with 3% bovine serum 
albumin in PBS-0.05% Tween-20 prior to incubation with 200 ng PRL3-zumab for 2 hours at 37°C. After 
extensive washing, HRP-conjugated anti-mouse antibody (Pierce) was added for 1 hour at 37°C. Colorim-
etric development was performed using a Turbo-TMB substrate (Pierce) and stopped by acidification with 
2 M H2SO4. Absorbance was measured at 450 nm using a plate reader (Dynatech).
Animal models. Eight-week-old male BALB/c nude mice obtained from the Biological Resource Centre 
(A*STAR) were used for all animal models in this study. Mice were anesthetized with 2.5% avertin (100 
μl/10 g body weight).
Orthotopic GC model. Abdomens of  anesthetized mice were opened in layers by a 1-cm midline incision 
starting from 0.5 cm below the xiphoid sternum. The stomach was taken out through the abdominal incision 
by surgical forceps, and equal numbers of  cancer cells from a master cell pool were injected into the subse-
rosa layer. The cell numbers required to induce orthotropic gastric tumors for each cell line and the duration 
of  experiments were confirmed after preliminary experiments: 3 × 106 cells for SNU-484 tumors and 5 × 
106 cells for IM-95, NUGC-4, MKN45, and MKN45-PRL-3 tumors. Subsequently, the stomach was placed 
back and the abdomen was sutured back in layers. Because of  the different growth rates of  the individual 
tumors, the duration of  experiments were as follows: 4 weeks for SNU-484, NUGC-4, and MKN45-PRL-3 
tumors, 8 weeks for MKN45 tumors, and 12 weeks for IM-95 tumors. The treatment regime commenced on 
day 2 after inoculation of  cancer cells in the gastric subserosa layer. For tumor growth/volume experiments, 
treated mice were administered i.v. with 100 μg of  PRL3-zumab or, where indicated, human IgG isotype 
control (catalog BE0092; Bio X Cell) diluted in 100 μl PBS twice a week, for a total of  8 times (SNU-484, 
NUGC-4, MKN45-PRL-3 tumors) or 10 times (IM-95, MKN45 tumors). Where indicated, 5-FU (Hospira) 
was administered i.v. via tail vein either alone or together with PRL3-zumab at a dose of  30 mg/kg biweekly 
for a total of  8 times. Tumor volumes were calculated using the formula volume = 0.4 × tumor length × 
tumor width × tumor width (62). For survival studies, treated mice were administered i.v. with 100 μg of  
PRL3-zumab diluted in 100 μl PBS twice a week, for a total of  10 times. Untreated mice were administered 
i.v. with an equivalent volume of  placebo (buffer alone) as a control. When mice displayed reduced physical 
activity and appeared ill, they were euthanized.
Xenograft tumor recurrence model. 3 × 106 SNU-484 cells in 150 μl of  PBS were injected into both flanks 
of  anesthetized mice. After 3 weeks, resultant tumors (0.5- to 1-cm diameter) were surgically removed 
under anesthesia, and mice were divided into treated or untreated groups to receive biweekly doses of  
either PRL3-zumab or placebo, respectively. Tumor recurrence, defined as the regrowth of  tumor with 
diameter greater than or equal to 1 cm at resection sites, was then monitored weekly in both groups up till 
10 weeks after resection. Tumor size was measured using calipers. Recurrence-free survival was analyzed 
by the Kaplan-Meier method.
Stomach xenograft colonization model. 3 × 106 HCT116-luc2 cells were directly implanted into the gastric 
serosa of  anesthetized mice, as described above. Mice were divided into treated or untreated groups, and 
tumor growth at weeks 1, 2, and 3 after implantation was monitored by IVIS imaging under 2% isoflurane 
anesthesia 15 minutes after intraperitoneal injection of  150 mg/kg luciferin (Caliper Life Sciences).
Analysis of  mouse blood samples. After smearing a thin layer from a drop of  fresh mouse blood on a glass 
slide, slides were baked at 37°C for 1 hour before flooding with modified Wright Giemsa stain (Sigma- 
Aldrich) for 1 minute followed by washing with deionized water for 3 minutes. After drying, the stained 
slides were observed under a light microscope (Olympus), with wbc stained blue. Estimation of  total wbc 
counts was performed by taking the average of  wbc from at least 10 visual fields in each slide, and calcula-
tion was performed using the equation wbc/μl = (total number of  counted wbc/number of  fields) × 2,000. 
Full hematological profiling of  mice blood samples was conducted by Quest Laboratories.
Antibodies. Calnexin (catalog 2679) antibody was purchased from Cell Signaling. CD63 (catalog 
sc-15363) antibody was purchased from Santa Cruz Biotechnology. GAPDH (clone MAB374) anti-
body was purchased from Millipore. HSP60 (catalog 611562) and HSP70 (catalog 610607) antibodies 
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were purchased from BD Pharmingen. HRP-conjugated anti-mouse (catalog 715-035-150), anti-rabbit 
(catalog 711-035-152), and anti-human (catalog 709-035-149) secondary antibodies were purchased from 
Jackson ImmunoResearch Inc.
Conditioned media analysis. Exponentially growing cells at 70% to 80% confluence in 5 T-75 culture 
flasks (Corning) were washed twice with serum-free RPMI before incubation with serum-free RPMI for 
48 hours. Conditioned media were centrifuged twice at 1,800 g for 10 minutes to remove floating cells and 
cellular debris. Clarified supernatants (50 ml) were subsequently concentrated ~250-fold (final volume ~0.2 
ml) using 3K MWCO spin concentrators (Millipore), quantitated, and analyzed by Western blotting.
Immunofluorescence imaging. Cells were seeded directly onto glass coverslips and grown for 48 hours. 
After washing twice with PBSCM (PBS pH 7.0, 1 mM MgCl2, 1 mM CaCl2), cells were fixed in 3% 
paraformaldehyde (Sigma-Aldrich) for 20 minutes at room temperature, washed, permeabilized for 15 
minutes with PBS-0.1% saponin (Sigma-Aldrich), and blocked in PBS-FDB (PBS pH 7.0, 2% BSA, 5% 
goat serum, 5% fetal bovine serum) for 1 hour at room temperature. Slides were subsequently incubated 
with PRL3-zumab at a 1:200 dilution at room temperature for 4 hours, washed, and incubated for 2 
hours with the AlexaFluor546-conjugated goat anti-human secondary antibodies (catalog A-21089; Ther-
moFisher Scientific). Washed slides were mounted with a DAPI-containing anti-fade mounting reagent 
(Vector Laboratories) and sealed using nail polish. Confocal imaging was performed with an LSM 510 
confocal microscope (Zeiss AG).
Immunohistochemistry. To analyze PRL-3 expression in normal human tissues, we used a commercial 
tissue microarray (catalog NC00-02-009; Cybrdi) containing 100, 4-μm-thick sections from different indi-
viduals verified for normal histology across 33 different tissue types. For tumor specimens, 10-μm-thick 
cryosection slides were fixed with 4% formalin for 20 minutes and incubated with 1% H2O2-PBS in the 
dark for 5 minutes. Washed slides were then blocked in PBS containing 10% goat serum and 1% BSA 
(Sigma-Aldrich) for 1 hour at room temperature. Subsequently, slides were washed 3 times in PBS-0.05% 
Tween-20 with gentle shaking and incubated with mouse anti–PRL-3 antibody (1:100 dilution) overnight 
at 4°C. After washing, HRP-labeled polymer (anti-mouse; Dako) was added for 2 hours before washing 
extensively and incubating with substrate-chromogen solution (Dako) for 10 to 20 minutes in the dark. 
Mounted slides were examined using a bright-field microscope (Olympus), and representative images were 
captured. For direct detection of  PRL3-zumab in tissues, slides were fixed and blocked as described above, 
incubated with HRP-labeled polymer (anti-human; Dako) without primary antibodies, and subsequently 
processed as described above.
Statistics. For human studies, the log-rank test was used to assess the significance of  the Kaplan-Meier 
analysis of  overall GC patient survival, based on PRL-3 mRNA expression grouping. Univariate and 
multivariate analyses were performed using Cox proportional hazards regression. For mouse studies, the 
log-rank test was used to assess significant differences in the Kaplan-Meier analysis of  overall survival 
between untreated and treated mouse groups. Tumor volumes and stomach IVIS luminescence intensities 
between untreated and treated mice were analyzed using 2-tailed Student’s t tests. ELISA measurements, 
tumor volumes, wbc counts, and fluorescence intensities of  B and NK cell infiltration among multiple treat-
ment groups were separately analyzed using 1-way ANOVA and, where indicated, post-hoc Tukey’s HSD 
test. Global IVIS luminescence intensities between treatment groups over time were analyzed by 2-way 
ANOVA. SPSS v19.0 (IBM) or Prism v4.0 (Graphpad Software) were used for statistical calculations. In all 
instances, P values less than 0.05 were considered significant.
Study approval. Mouse studies were approved by the Biological Resource Centre (A*STAR) Institu-
tional Animal Care and Use Committee and performed in accordance with their approved guidelines 
and regulations. Fresh-frozen primary human gastric tumors and corresponding normal tissue samples 
were acquired, with patient consent, from the National University Hospital–National University of  Singa-
pore Tissue Repository. The collection and use of  human tissue samples were approved by the IRB of  the 
National University of  Singapore and National Healthcare Group, Singapore.
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